Immune surveillance and response to JC virus infection and PML.
about
Animal Models for Progressive Multifocal LeukoencephalopathyThe importance of mouse models to define immunovirologic determinants of progressive multifocal leukoencephalopathyPET Imaging of 18F-FDG, 11C-methionine, 11C-flumazenil, and 11C-4DST in Progressive Multifocal LeukoencephalopathyPersistence and pathogenesis of the neurotropic polyomavirus JCPur-Alpha Induces JCV Gene Expression and Viral Replication by Suppressing SRSF1 in Glial Cells.Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV ReactivationExpression of Signaling Molecules in Progressive Multifocal LeukoencephalopathyProgressive Multifocal Leukoencephalopathy in Primary Immune Deficiencies: Stat1 Gain of Function and Review of the Literature.Diagnostic assays for polyomavirus JC and progressive multifocal leukoencephalopathyImmunology of progressive multifocal leukoencephalopathy.Treatment options for progressive multifocal leukoencephalopathy in HIV-infected persons: current status and future directions.Disease activity return after natalizumab cessation in multiple sclerosis.Immune reconstitution inflammatory syndrome in HIV infection: taking the bad with the good.Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies.Anti-JC virus seroprevalence in a Finnish MS cohort.JC Polyomavirus Attachment and Entry: Potential Sites for PML Therapeutics.Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.
P2860
Q26853218-3A1EE00E-31B5-480A-BB76-43CA90B9BBE4Q26859307-5B567E31-BA1D-439A-B36D-4BD5078623DFQ32182145-46EFE137-F394-44D9-8F03-C61B6672D4B7Q34459843-B3C763B5-2C62-4353-B244-DAF646D9AF01Q34529503-3A155312-258A-4B9B-B000-B2C2841F36F4Q36093592-D14696B5-8473-4597-AC0E-22B98E550098Q36318597-D6D3FB07-892E-4E2E-A2A4-B34190FF37D3Q36715809-30F36C9B-A718-429A-B107-D35448758943Q36942417-5B874063-3EC1-4780-B0BD-575FB9A17018Q38367755-44FAD489-E3FF-4B2C-B1E7-1F21573DBAC6Q38665891-0420D4FE-AD64-4CA4-B824-6B51DEF00985Q38779091-03332214-486E-4A15-BAAA-2F9C615DB76FQ38995954-39B96EC8-DF15-470F-8A1C-1BB829A1F632Q40039520-247961B6-E56A-4413-84F7-1E03E547C375Q40565210-DA088E44-7A3F-4311-A5D4-41CC9B782FC1Q41921811-66A2138B-2E49-4E33-BCD0-D18D3FE1AEB8Q50543805-38DC19F6-5AE1-4F43-8573-3116B3E8FF59
P2860
Immune surveillance and response to JC virus infection and PML.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immune surveillance and response to JC virus infection and PML.
@en
Immune surveillance and response to JC virus infection and PML.
@nl
type
label
Immune surveillance and response to JC virus infection and PML.
@en
Immune surveillance and response to JC virus infection and PML.
@nl
prefLabel
Immune surveillance and response to JC virus infection and PML.
@en
Immune surveillance and response to JC virus infection and PML.
@nl
P2860
P1476
Immune surveillance and response to JC virus infection and PML.
@en
P2093
Jennifer Gordon
Sarah Beltrami
P2860
P2888
P304
P356
10.1007/S13365-013-0222-6
P577
2013-12-03T00:00:00Z